Anticoagulation in cancer patients; new recommendations based on randomized clinical trials
{{output}}
Venous thromboembolic disease (VTD) is currently the second leading cause of death in cancer patients with a prevalence of approximately 20% compared with that of 5% in the entire adult population. Cancer patients are a heterogeneous group with significant dif... ...